Results 61 to 70 of about 755,616 (163)
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz +45 more
wiley +1 more source
Development of a Selective Labeling Probe for Bruton’s Tyrosine Kinase Quantification in Live Cells
As a key regulator of the B-cell receptor signaling pathway, Bruton’s tyrosine kinase (Btk) has emerged as an important therapeutic target for various malignancies and autoimmune disorders.
Zhengying Pan (1717066) +3 more
core +1 more source
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov +19 more
wiley +1 more source
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima +20 more
wiley +1 more source
Supplemental material, Supplementary_Material for A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase by L. L. Ong, J. D. Vasta, L. Monereau, G. Locke, H. Ribeiro, M. A.
B. Arey (7844306) +16 more
core +1 more source
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) [PDF]
International audienceRecent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor signaling pathway [1, 2].
Morschhauser, Franck +22 more
core +1 more source
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart +15 more
wiley +1 more source
Molecular Dynamic Simulation data of compensatory mutations in Bruton's Tyrosine Kinase
The research aims to find compensatory mutations that rescue Bruton’s tyrosine kinase (Btk) activity in the presence of severe X-linked agammaglobulinemia (XLA) causing mutation in the kinase domain. The data set includes the molecular dynamic simulation
Nikita Chopra (2580964) +3 more
core +1 more source
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini +24 more
doaj +1 more source
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo +18 more
doaj +1 more source

